A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Spartalizumab (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Acronyms COMBI-i
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 13 Jun 2024 This trial has been completed in Hungary according to European Clinical Trials Database record.
- 03 Jun 2024 Planned End Date changed from 2 Aug 2024 to 26 Aug 2024.